One sentence summary: Butyrate-producing bacteria are promising probiotic candidates to maintain gastrointestinal health. Here, the behavior and butyrogenic effect of such a candidate was assessed in a model for the gut microbiota. Editor: Julian R. Marchesi ABSTRACT Butyrate-producing bacteria are promising probiotic candidates to target microbial dysbiosis in gastrointestinal disorders like inflammatory bowel diseases. Butyricicoccus pullicaecorum 25-3 T , a butyrate-producing clostridial cluster IV strain, is such a candidate. Little is known about its abundance in the colon microbiota and its butyrogenic properties. We used the M-SHIME R , an in vitro simulator for the human intestinal microbial ecosystem, to study the effect of supplementing a single dose of B. pullicaecorum 25-3 T on lumen-and mucus-associated microbiota of eight individuals. Butyricicoccus pullicaecorum was more abundant in mucus-associated microbiota compared with lumen microbiota. Supplementation with a single dose of B. pullicaecorum 25-3 T resulted in a temporary increase in B. pullicaecorum bacteria in lumen compartment of all individuals. In two cases, the responders, an increased butyrate production was observed as compared with the control. 16S rRNA gene amplicon sequencing revealed the microbiota of responders to be different as compared to non-responder microbiota. We can conclude that B. pullicaecorum 25-3 T is a mucus-associated bacterium whose potency to stimulate butyrate production is characterized by a large interindividual variability in terms of composition of the receiving microbial community.
INTRODUCTION
The human gastrointestinal tract contains up to 100 trillion (10 14 ) microbes which live in homeostatic symbiosis with their host and contribute to its health (Bäckhed et al. 2005) . Microbial dysbiosis is defined as a shift of the microbial composition and activity from a normal, beneficial state to one that could influence human health and contribute to disease (Frank et al. 2011b; Walker and Lawley 2013) . The onset and duration of several intestinal and systemic disorders have been linked to microbial dysbiosis (Alonso and Guarner 2013; Walker and Lawley 2013) . This is also the case for inflammatory bowel diseases (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), which are characterized by a chronic, relapsing inflammation of the gastrointestinal tract. Microbial dysbiosis in IBD can be described by a loss in diversity of the dominant bacterial phyla (particularly Firmicutes), increased numbers of Proteobacteria and Actinobacteria and reduced numbers of anaerobic Firmicutes bacteria (Manichanh et al. 2006; Frank et al. 2007; Willing et al. 2010; Lepage et al. 2011) . The reduction in Firmicutes bacteria can be explained by the observed loss in butyrateproducing Firmicutes bacteria from clostridial cluster IV and XIVa. Butyrate is important to maintain gastrointestinal health, because it serves as the main energy source for colonocytes, enhances epithelial barrier integrity and inhibits inflammation (Hamer et al. 2008) . Therefore, it has been suggested to target microbial dysbiosis by supplementing butyrate-producing bacteria to restore homeostasis and health in IBD (Van Immerseel et al. 2010) .
Butyricicoccus pullicaecorum 25-3 T is a butyrate-producing strain of the family Ruminococcaceae (clostridial cluster IV) with potential probiotic characteristics (Eeckhaut et al. 2008) . While the genus Butyricicoccus is decreased in abundance in stool samples of IBD patients, B. pullicaecorum 25-3 T is able to attenuate chemically induced colitis in a rodent IBD model . In an in vitro study, we demonstrated a good intrinsic tolerance of B. pullicaecorum 25-3 T to stomach and small intestinal conditions which makes it suitable for probiotic application (Geirnaert et al. 2014) .
To further assess the probiotic use of B. pullicaecorum 25-3 T , it is important to know its behavior in the presence of a complex microbial community under colon conditions. In vitro models which simulate the human microbiota are a good tool to study the change in composition and metabolic activity after treatment with a probiotic, prebiotic or other compound without the influence of the host (Venema and van den Abbeele 2013) . The M-SHIME is such a model which simulates the mucus and lumen human intestinal microbial ecosystem (Van den . The advantages of the M-SHIME over other common in vitro models are the incorporation of a mucus environment, conservation of butyrate-producing bacteria, and maintenance of interindividual differences in composition and activity of the microbiota in vitro (Van den . It has previously been used to study the colonization of microbiota of UC patients (Vermeiren et al. 2012; Vigsnaes et al.2013) .
Here, we use the M-SHIME to assess the colonization potential of B. pullicaecorum T and to analyze its impact on butyrate production by the microbiota of different individuals healthy volunteers (HV and CD patients in remission) after B. pullicaecorum 25-3 T administration. We applied a single dose of B. pullicaecorum 25-3 T to monitor its growth or washout from the microbial communities during the 10-day followup period and effect of composition of receiving microbial community.
MATERIALS AND METHODS

Bacterial strain, growth conditions and preparation treatment
Butyricicoccus pullicaecorum 25-3 T (LMG 24109 T ) was grown in anaerobic M2GSC medium at pH 6 prepared as described by Miyazaki et al. (1997) but with 15% (v/v) of clarified rumen fluid instead of 30% (v/v). M2GSC agar (1.5% w/v) plates were incubated at 37
• C in an anaerobic (10% CO 2 , 90% N 2 ) workstation (GPCampus, Jacomex, TCPS NV, Rotselaar, Belgium) for 20 h. Before use in each experiment, a B. pullicaecorum colony was transferred into 10 mL of anaerobic M2GSC broth and incubated overnight at 37 • C. Subsequently, the culture was subcultured (10% v/v) once in 500 mL of anaerobic M2GSC broth and incubated for 20 h at 37
• C. The B. pullicaecorum culture was concentrated from 500 to 10 mL by centrifugation (10 min, 1500 g). The supernatant was removed and the pellet was resuspended in 10 mL of anaerobic phosphate-buffered saline (PBS per L: 8.8 g K 2 HPO 4 , 6.8 g KH 2 PO 4 , 8 g NaCl, 1 g cysteine-HCl) to supplement to M-SHIME colon vessels. This suspension contained 9.9 log B. pullicaecorum copies/mL. Growth requirements of B. pullicaecorum 25-3T are the presence of fermentable sugars and yeast extract; butyrate production is stimulated by exogenous acetate. All of these compounds were present in the suspension from M-SHIME colon vessels.
Fecal bacteria from human volunteers
Fecal bacteria of three healthy individuals (HV 1-HV 3, aged 23-37) and five CD patients in remission (no active inflammation) for more than 12 months (CD 1-CD 5, aged 24-41) were prepared to inoculate M-SHIME. The study was approved by the Ethics Committee of the University Hospital Ghent (permit numbers EC UZG 2006 /377 & EC UZG 2012 , and all volunteers received and signed an informed consent form. None of the donors had received antibiotics or probiotics for at least 3 months before fecal sample donation. CD 1-CD 3 received maintenance treatment with azathioprine (immunosuppressive drug) and CD 4 and CD 5 had not taken any medication since 8 months before sample donation. CD 2, CD 4 and CD 5 had a history of ileitis, CD 1 and CD 3 had a history of ileocolitis. Fecal samples were collected in airtight containers together with one AnaeroGen sachet (Oxoid) to maintain anoxic conditions until start of incubation. Time between fecal sample donation and start of incubation was maximum 2 h. A 20% (m/v) fecal suspension was prepared by homogenizing the fecal sample with 0.1 M anaerobic phosphate buffer (per L: 8.8 g K 2 HPO 4 , 6.8 g KH 2 PO 4 and 1 g C 2 H 3 O 2 Sna, pH 6.8) in a stomacher for 2 min. After removing particulate material by centrifugation (2 min at 500 g), the suspension was used as inoculum for incubation.
Simulation of lumen-and mucus-associated microbiota-M-SHIME
The behavior of B. pullicaecorum was studied in the M-SHIME, a dynamic in vitro model which simulates the lumen-and mucusassociated human intestinal microbial ecosystem (ProDigestGhent University, Ghent, Belgium) (Van den . This model consists of pH controlled, stirred (200 rpm), airtight, double-jacketed glass vessels kept on 37
• C and under anaerobic conditions by daily flushing with N 2 (15 min). The set-up used in this study consisted of a stomach and a small Figure 1 . Overview of experimental set-up of simulation mucosal and luminal microbiota in M-SHIME. In total eight simulations of 17 days were performed starting with fecal microbiota of eight different individuals. Treatment vessels were supplemented on day 7 with one dose of B. pullicaecorum (10 9 /mL).
intestine vessel and two colon vessels (control and treatment) in parallel for each studied donor (Fig. 1) . The system was operated and simulation media were prepared as described earlier (Van den . The colon vessels were inoculated at the start with 40 mL fecal suspension in 500 mL sterile nutritional medium (per L: 3 g yeast extract, 1 g special peptone (Oxoid), 4 g commercial porcin gastric mucin (Sigma) and 0.5 g L-cystein).
After an initial static incubation of 18 h, 140 mL sterile nutritional medium at pH 2 per colon vessel was supplemented to the stomach vessel: this procedure was conducted three times a day. Stomach digest suspension was pumped into the small intestine vessel together with 60 mL pancreatic juice [per L: 12.5 g NaHCO 3 , 6 g dehydrated bile extract (Oxgall, Difco) and 0.9 g pancreatin (Sigma)] per colon vessel. Small intestinal digest suspension was distributed over the different proximal colon vessels, which contained simulated colon microbiota. To simulate colon conditions, the residence time in the colon vessels was 20 h and pH was controlled at pH 6.15-6.40 which are both in the range of in vivo observations (Metcalf et al. 1987; Nugent et al. 2001) . Mucus microbiota were simulated by adding carriers coated with agar containing commercial available porcine gastric mucin (Sigma, Bornem, Belgium) which is a crude stomach extract containing mucin types MUC5AC and MUC6. The mucin type in colon mucus is mainly MUC2 but is not commercial available. The mucinagar beads serve as a glycoprotein contact surface which results in a better simulation of the colon microbiota. To each colon vessel, 60 mucin agar-covered microcosms in a polyethylene netting were added. Mucin agar consisted of 5% (m/v) commercial pig gastric mucin and 1% (m/v) agar. Every two to three days, two-third of the mucin agar-covered microcosms were replaced by fresh sterile ones under a flow of N 2 to prevent disruption of anaerobic conditions. Seven days after inoculation, colon vessels were inoculated with 10 mL B. pullicaecorum culture (10 9 bacteria/mL) (treatment vessels) or 10 mL sterile anaerobic PBS (control vessels). After treatment there was a follow-up period of 10 days. Lumen samples were taken every day, and mucin agar samples were taken every two to three days. Mucin agar-covered microcosms were washed with sterile PBS to remove lumen bacteria. Mucin agar was removed from microcosms, homogenized and stored immediately at −20
• C until further analysis.
Previous studies showed a good reproducibility of the SHIME (Van den Abbeele et al. 2010) . To validate the reproducibility during this study with an M-SHIME, we used the fecal slurry of two individuals (CD 5 and HV 3) to inoculate each two identical M-SHIME colon vessels. Short-chain fatty acid (SCFA) concentrations in lumen samples of replicates were similar Downloaded from https://academic.oup.com/femsec/article-abstract/91/6/fiv054/2594601 by guest on 10 December 2018 during the experiment of 17 days and confirmed reproducibility (Fig. S1 , Supporting Information).
SCFA analysis
The SCFA in the lumen samples of the M-SHIME were extracted with diethyl ether and analyzed using a gas chromatograph as described by De Weirdt et al. (2010) . The concentration in mM of acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, caproate and isocaproate was determined in each sample. The concentration of acetate and butyrate was expressed as mol% which is the ratio of the concentration of acetate or butyrate (mM) and the total SCFA concentration (mM) multiplied by 100 in the sample.
DNA extraction
Liquid samples (1 mL fecal suspension and 1 mL lumen M-SHIME) for total DNA extraction were centrifuged for 10 min at maximum speed, supernatant was removed and pellet was stored immediately at −20
Total DNA was extracted from pellet of 1 mL liquid samples and 0.5 g mucin agar following a protocol adapted from VilchezVargas et al. (2013) . Cells were lysed with 1 mL lysis buffer (100 mM Tris/HCl pH 8.0, 100 mM EDTA pH 8, 100 mM NaCl, 1% (m/v) polyvinylpyrrolidone and 2% (m/v) sodium docecyl sulphate) and 200 mg glass beads (0.11 mm, Sartorius) in a FastPrep R -96 instrument (MP Biomedicals, Santa Ana, USA) for two times 40 s (1600 rpm). After removing glass beads by centrifugation (5 min at maximum speed), DNA was extracted from supernatant following a phenol-chloroform extraction. DNA was precipitated with 1 volume ice-cold isopropyl alcohol and 0.1 volume 3 M sodium acetate for at least 1 h at −20
• C. After removal of isopropyl alcohol by centrifugation (30 min, maximum speed), the DNA pellet was dried and resuspended in 100 μL (fecal sample) or 30 μL (M-SHIME sample) 1× TE (10 mM Tris, 1 mM EDTA) buffer. After finishing the extraction protocol, DNA samples were immediately stored at −20 • C until further analysis.
Quality of DNA samples was analyzed by 1% (w/v) agarose (Life technologies, Madrid, Spain) gel electrophoresis. DNA was quantified by a fluorescence assay with the QuantiFluor R ds-DNA kit (Promega, Madison, USA) and Glomax R -Multi + system (Promega, Madison, USA).
qPCR
Total bacterial 16S rRNA gene and species specific 16S rRNA gene of B. pullicaecorum was quantified with qPCR in 100-fold diluted DNA extracts of fecal and M-SHIME samples. All qPCR assays were performed on a StepOnePlus Real-Time PCR system (Applied Biosystems, Carlsbad, CA). The amplification reactions were carried out in triplicate in a volume of 25 μL which contained 20 μL of in-house prepared mastermix and 5 μL of DNA template. The in-house prepared mastermix was comprised of 1× Colorless GoTaq R reaction buffer (Promega), 1.5 mM MgCl 2, 200 nM dNTP mix, 200 nM of each forward and reverse primer, 0.625 U GoTaq HotStart polymerase (Promega) and 0.1× SYBR R Green I (Invitrogen, provided at 10 000×, stock solutions of 20× were prepared in DMSO). Primers for total Bacteria (PRBA 338f and 518r) amplified a 180-bp amplicon of V3 region of the 16S rRNA gene (Ovreas et al. 1997) . Cycling program for total bacteria was as follows: 3 min at 95
• C followed by 
Illumina
The V3-V4 region of the 16S rRNA gene was amplified with primer pair 341F and 785R, with dual multiplex identifier and adaptors as described by Kozich et al. (2013) . Sequencing was performed using Illumina MiSeq sequencer and sequencing kit MiSeq V3 to produce 300-bp pair-end reads. After demultiplexing, fastq sequences were merged using FLASH (Magoc and Salzberg 2011) software with default parameters, and successfully combined reads were filtered based on quality (>90% of nucleotides must have quality score 30 or higher for every read) using Fastx tool kit (http://hannonlab.cshl.edu/fastx toolkit/). A minimum of 3000 reads was obtained for each sample included in the study. Chimeras were removed using UCHIME (Egdar 2013) and each sample was standardized to 3000 reads using random selection of reads. The taxonomy of reads was determined using RDP classifier (Wang et al. 2007 ) and species-level OTUs (taxonomical bins of sequences with >97% similarities) were created using USEARCH pipeline (Edgar 2013) , and genus/OTU tables were created using Perl scripts. Detailed information on microbiome analysis results can be found in supplementary information.
Statistical analysis
All statistical analyses were performed in R. Bray-Curtis dissimilarity was the major beta-diversity measure used in this study and was calculated using package 'vegan' (Dixon 2003) ; alpha diversity measures included Chao1 richness measurement, observed number of genera/OTUs and Shannon evenness, all calculated in 'vegan' as well. 'adonis' (analysis of dissimilarity, multidimensional ANOVA of distance matrices) was used to determine the variation explained by different factors tested in the study, as well as the significances. Constrained analysis of principal coordinates ('capscale', Anderson and Willis 2003) was used to perform coordination of samples according to the variable being tested and determines the relative importance of difference variables. pullicaecorum (log copies/mL or /g) in lumen and mucus samples of control (C) and treatment (T) vessels before treatment (B1), 3 days after treatment (B2) and 10 days after treatment (B3). Each data point represents an individual M-SHIME sample. Triangles indicate HV samples and circles indicate CD samples. Limit of detection (LOD) is indicated by gray horizontal line. Significant differences are indicated by asterisks with * * = P < 0.001; * * * = P < 0.0001 and ns = non-significant.
RESULTS
Relative B. pullicaecorum abundance increased in the mucus-associated microbial community compared with lumen microbial community of the M-SHIME
Colon vessels of the M-SHIME were inoculated with fecal suspensions of one individual and in total eight incubations were performed with fecal suspensions of eight different individuals (CD1-5; HV1-3). During a period of 7 days, fecal bacteria were able to colonize the lumen and/or mucus environment of the in vitro model. The concentration of bacteria (total 16S rRNA gene) and indigenous B. pullicaecorum (species-specific 16S rRNA gene assay) was determined by qPCR to determine the initial levels of B. pullicaecorum before supplementation. Fecal concentrations of total bacteria ranged from 7.9 to 10.1 log copies/mL with a median at 9.9 copies/mL. Lumen concentrations of total bacteria on day 7 ranged from 7.6 to 9.0 log copies/mL with a median at 8.5 log copies/Ml, while mucus concentrations ranged from 8.9 to 9.9 log copies/g with a median of 9.4 log copies/g. Fecal concentrations of B. pullicaecorum ranged from 5.2 to 8.0 log copies/mL with a median at 6.6 log copies/mL. Lumen concentrations of B. pullicaecorum varied from 4.3 to 6.2 log copies/mL with a median at 5.5 log copies/mL, while mucus concentrations ranged from 6.3 to 7.8 log copies/mL with a median at 7.2 log copies/mL. Overall, there was no difference in concentration of total and B. pullicaecorum bacteria between CD and HV microbiota in the M-SHIME (data not shown). The ratio of B. pullicaecorum 16S rRNA gene copies to total 16S rRNA gene copies was used to calculate the relative abundance of B. pullicaecorum in the lumen-versus mucus-associated microbiome. Butyricicoccus pullicaecorum was relatively more abundant (P < 0.0001) in mucus microbial community (0.85 ± 0.14%) than the lumen microbial community (0.16 ± 0.03%) ( Fig. 2A) .
Treatment of microbial communities with single dose B. pullicaecorum 25-3 T
On day 7, the treatment vessels were supplemented with a single dose of B. pullicaecorum 25-3 T (on average 9 log copies/mL M-SHIME suspension). Before supplementation, there was no difference in average concentrations of total bacteria and B. pullicaecorum in lumen and mucus samples of treated vessels (0) compared with control vessels (Fig. S2 , Supporting Information and Fig. 2 B1) . Three days after treatment, the mean concentration of B. pullicaecorum was higher (P = 0.005) in lumen of treated vessels compared with control vessels (Fig. 2B2) . This was not the case in mucus samples. If we compare treatment with control concentrations in each individual microbial community, there were more B. pullicaecorum in mucus samples of treated vessels compared with control in four out of eight cases (Fig. S3 , Supporting Information). Ten days after supplementation, B. pullicaecorum concentration in the treated vessels was similar to those in the control vessels (Fig. 2B3 ). Based on 16S rRNA gene amplicon sequencing, we observed a clear increase in Butyricicoccus spp. sequences in treated lumen and mucus samples of CD 1, CD 4, CD 5, HV 1, HV 2 and HV 3 3 days after treatment (Table S1 , Supporting Information). Seven days after treatment, Butyricicoccus sequences were still higher in mucus samples of treated vessels compared to control of CD 4, CD 5, HV 1, HV 2 and HV 3.
SCFA profiles show interindividual differences after treatment with B. pullicaecorum 25-3 T SCFA concentrations were determined in lumen samples to evaluate the metabolic activity of the different microbial communities in the M-SHIME. The mean concentrations of total SCFA during the start-up period (day 3-day 7) ranged from 38.6 (±2.8) to 58.5 (±4.2) mM in the 16 M-SHIME vessels (Table 1) . There were interindividual differences in the SCFA profile. The relative concentration of acetate/propionate/butyrate for example ranged from 50%/20%/20% (CD 3, control) to 73%/13%/11% (HV1, control). Higher interindividual differences were observed in case of branched chain fatty acids (BCFA) levels (1-10%). There was no difference in SCFA profiles between control and treatment vessels of each corresponding donor microbial community. SCFA profiles of CD microbiota were comparable to those of HV microbiota in the M-SHIME. On average, single dose of B. pullicaecorum 25-3 T did not increase SCFA production during a 10-day followup period (Table 1 ). In two cases (CD 5 and HV 1), a clear difference in SCFA profile was observed between treatment and control (Fig. 3) . In case of donor CD 5, the relative concentration of acetate started to decrease after 4 days of supplementation to 53% (day 14, control level 74%), whereas the relative concentration of butyrate increased to a level of 18% (day 14, control level 8%). In case of donor HV 1, the relative concentration of acetate decreased to 53% (day 13, control level 71%) and the relative concentration of butyrate increased to 22% (day 13, control level 7%).
Non-treated M-SHIME microbiota of responders is different from non-responders
To investigate the basis of differences in butyrate/acetate production, we defined groups of 'responders' (RS, samples that responded to the inoculation and showed increase in butyrate production compared to controls without inoculations, i.e. CD5 and HV1) and 'non-responders' (NR, the rest). We did not find significant differences in alpha-diversity between NR and RS samples (Wilcox test P > 0.05 in lumen and mucus). However, significant differences were observed between RS and NR samples from the control lumen (21.9% variation in genus and 15.0% variation in OTU, P = 0.002 and 0.004, respectively) and mucus (23.6% variation of genus and 24.4% variation of OTU, both P = 0.002, Fig.  4) were found, indicating a distinct profile for non-treated RS microbiome. We analyzed the major genera (those with average abundance >0.5% in the control samples, n = 24) using Wilcox test and discovered four genera with significant differences (P < 0.05) between the NR and RS control samples in the lumen and seven in the mucus (Fig. 5) . With same approach, 11 OTUs were identified in the lumen and 3 belong to genera identified above (Anaeroglobus, Lachnospiraceae and Ruminococcaceae); while in mucus 12 OTUs were identified and 5 belong to genera identified above (Anaeroglobus, Cloacibacillus, Citrobacter, Lachnospiraceae and Ruminococcaceae). In the NR group, no significant differences were found between samples after treatment and control (all P > 0.05), nor in the mucus samples of the RS samples; nevertheless, significant differences were found between the lumen samples of the treatment and control in the RS group (33.5% variation in genus variation, P = 0.035, but not in OTU P = 0.221). We examined the major genera (defined using same criteria as above, n = 21) using Wilcox test between the RS control samples and treatment samples, where we found three genera exhibiting significant differences between control and treatment (Fig. 6) . A significant increase of Anaeroglobus and Sutterella was found in the RS after treatment, while Citrobacter decreased, and no significant changes were found in the NR (Fig. 6) . Analysis at OTU level identified one OTU confirming the increase Anaeroglobus in RS samples, while one OTU belonging to Citrobacter showed significant decrease in RS samples.
DISCUSSION
The objective of this study was to assess the in vitro colonization preference of indigenous B. pullicaecorum from eight individuals and evaluate the colonization ability of a B. pullicaecorum isolate 25-3 T in the lumen-and mucus-associated microbiome after a single supplementation. We further assessed whether a single dose of B. pullicaecorum 25-3 T resulted in increased butyrate production by the in vitro simulated gut microbiome. Finally, the effect of the inoculation of B. pullicaecorum 25-3 T on the microbiota composition was analyzed.
Butyricicoccus pullicaecorum was more abundant in mucin-associated microbiota of the M-SHIME which is a first indication that it will also associate with the mucus layer in the gut. This confirms previous studies where the genus Butyricicoccus was detected in human mucus biopsy samples, Nava et al. reported Butyricicoccus at mean relative abundances of 1-2% (Frank et al. 2011a; Nava and Stappenbeck 2011; Durbán et al. 2012; Harrell et al. 2012; Ng et al. 2013) . This corresponds with the mean relative abundance of B. pullicaecorum in the mucin-associated microbiota of 0.85% in our study. Association with the intestinal mucosa is a key characteristic in selection of novel probiotic bacteria because it is considered important for immune modulation, resistance to pathogen colonization, enhanced mucosal healing and prolonged residence time in the gut (Ouwehand, Salminen and Isolauri 2002; Atarashi et al. 2011) . The relative abundance of B. pullicaecorum in lumen M-SHIME samples (0.02-0.34%) was comparable with previously reported relative abundances of Butyricicoccus spp. in human fecal samples (0.05-0.4%) (Claesson et al. 2012; Schnorr et al. 2014) . We conclude that Butyricicoccus has affinity for colonizing the mucus environment.
Supplementation with a single dose of B. pullicaecorum 25-3 T resulted in a temporary increase in B. pullicaecorum bacteria in lumen microbiota of all individuals. With the species-specific qPCR assay, we are not able to distinguish the supplemented B. pullicaecorum 25-3 T strain from the endogenous B. pullicaecorum
strains. An overview of strategies to detect and develop strainspecific PCR assays for probiotics was recently published (Treven 2015) . The identification of strain-specific genomic markers after comparison of the whole genome of target strain with related genomes in public databases is a promising strategy we should consider in future assays. The difference in B. pullicaecorum concentration between treated and non-treated colon compartments was gone 10 days after treatment. This indicates that B. pullicaecorum T is only able to temporarily colonize the microbiota after a single supplementation. The persistence of traditional probiotics, Lactobacillus and Bifidobacterium species, is also generally low . For example, in a trial with Lactobacillus reuteri, the supplemented strain was no longer detected in the majority of participants 4 days after stopping the treatment (Rattanaprasert et al. 2014) . To successfully colonize the gut microbiota, the supplemented species has to compete with the established resident microbiota for niches and nutrients . The mucosal niche is thought to be saturable and will already contain a specific population (Gibson, Pesesky and Dantas 2014) , which makes it challenging for exogenous strains to colonize that niche. The colonization resistance of the resident microbiota towards exogenous strains can be obtained through physical exclusion and/or production of antimicrobials, but will also depend on interindividual differences in composition of the endogenous microbiome. For example, in a doubleblinded, placebo-controlled crossover study with vaginal administration of two probiotic Lactobacillus strains, the supplemented strains were only detected in 7 of 12 cases after probiotic treatment (Bisanz et al. 2014) . Such studies correspond with our finding of a variable success in B. pullicaecorum 25-3 T colonization in the eight human-derived microbiota. We identified two RS microbiota that displayed a clear increase in butyrate levels upon the single supplementation of B. pullicaecorum T , compared to non-treated microbiota. It is noteworthy that RS microbiota already displayed lower butyrate levels than NR microbiota prior to the treatment. Interestingly, the increase in butyrate levels for the RS microbiota was concomitant with a decrease in acetate levels. This indicates the presence of cross-feeding which is the metabolic interaction between acetate-consuming and butyrate-producing microbiota (De Vuyst and Leroy 2011) . It is known that many butyrate-producing bacteria, including B. pullicaecorum, follow the butyryl-CoA: acetate CoA-transferase pathway (Vital, Howe and Tiedje 2014) , which converts intra-and extracellular acetate and intracellular butyryl-CoA into butyrate and acetyl-CoA (Louis and Flint 2009) . Only two out of eight microbiota were responsive to B. pullicaecorum supplementation in terms of butyrate production. Studies with murine models reported a general increase in butyrate production after treatment with butyrate-producing Clostridium tyrobutyricum, Butyrivibrio fibrisolvens or Eubacterium limosum (Okamoto et al. 2000; Asanuma, Kawato and Hino 2001; Ohkawara et al. 2005; Kanauchi et al. 2006; Possemiers et al. 2008; Hudcovic et al. 2012) . However, the variability in response was not characterized as biological specimens from different animals were pooled. It is not clear in our study whether higher butyrate levels in the RS microbiota result from a direct effectbutyrate production by supplemented B. pullicaecorum 25-3 T -or an indirect effect-stimulation of the butyrate-producing community by supplemented B. pullicaecorum 25-3 T . While the SHIME model has been successful in demonstrating increased butyrate production upon supplementation of the butyrate-producing E. limosum (Possemiers et al. 2008) , the impact on the endogenous microbiome needs further characterization. The original (non-treated) composition of lumen and mucus microbiota from RS and NRs revealed significant differences. A couple of genera were significantly increased or decreased but no clear specific phylogenetic background was identified. With respect to the change in RS microbiota upon B. pullicaecorum treatment, Anaeroglobus and Sutterella were the two genera that significantly increased compared to the control. Anaeroglobus is a relatively new taxon and is reported to have the ability to produce butyrate; the butyrate-producing ability of the Sutterella genus is less clear (Carlier et al. 2002) . The role of the genus Sutterella in IBD or other gastrointestinal disorders is not clear. There was no difference in its abundance in mucosal biopsies of UC or celiac disease patients compared to healthy controls (Mukhopadhya et al. 2011; Cheng et al. 2013) . However, in a study with pouchitis and CD-like patients, Sutterella was described as one of the genera detected less frequently among patients compared to non-inflamed control (Tyler et al. 2013) . Phylogenetically different species in the human gut can perform similar (metabolic) functions and this leads to a functional core microbiome instead of a phylogenetic core microbiome (Lozupone et al. 2012) . This functional redundancy makes it difficult to link the observed differences in composition of the RS microbiota to its function. Therefore, it is not yet clear what explains the effect of the treatment with B. pullicaecorum 25-3 T on butyrate production in the two RS microbiota. We can conclude that B. pullicaecorum is an efficient colonizer of the mucus environment. While a single treatment with B. pullicaecorum 25-3 T did not result in a persistent colonization, it was effective in increasing B. pullicaecorum levels in mucus in four out of eight cases up to 10 days after treatment, and in stimulating butyrate production in two out of eight cases. While the original (non-treated) RS microbiota significantly differed from NR microbiota and shifts in the RS microbiome were noted upon B. pullicaecorum 25-3T administration, the factors for explaining the variability in response need to be investigated in studies with more individuals.
